Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This drove our attention to unravel the possible involvement of PI3k/Akt/mTOR pathway in the neuroprotective effect of crocin against rotenone (ROT)-induced PD in rats.
|
31811872 |
2020 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, our data shows conversion from an M1- to M2-like phenotype in LPS-activated microglia by β2-AR agonists involves activation of the classical cAMP/PKA/CREB as well as the PI3K and p38 MAPK signaling pathways, and provides a novel therapeutic approach targeting microglial cell activation and inducing their phenotypic conversion in the treatment of neuroinflammatory diseases such as PD.
|
30933849 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study suggests that the downregulated lncRNA UCA1 ameliorates the damage of dopaminergic neurons, reduces oxidative stress and inflammation in PD rats through the inhibition of the PI3K/Akt signaling pathway.
|
31301558 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of Vasicinone against Paraquat-Induced MAPK/p53-Mediated Apoptosis via the IGF-1R/PI3K/AKT Pathway in a Parkinson's Disease-Associated SH-SY5Y Cell Model.
|
31331066 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of PI3K-Akt-mTOR signaling pathway leads to a decrease in the expression of JNK3, which protects dopaminergic neurons and improves PD.
|
30783448 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore its possible mechanism in PD, we used 6-hydroxydopamine (6-OHDA, 8 μg) to mimic dopaminergic (DA) neuronal damage and validated this model in vivo and in vitro. in vivo, we detected an effect of PC (60 mg/kg) on the behavioural changes exhibited in 6-OHDA model rats, the number of DA neurons and the phosphorylation of protein kinase B (Akt). in vitro, we detected changes in cell viability, mitochondrial membrane potential (MMP) and total superoxide dismutase (SOD) and explored the role of PC (50 μM) by inhibiting the phosphoinositide 3-kinase (PI3K)/Akt signalling pathway with LY294002 (20 μM).
|
30925459 |
2019 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Treatment with T3s, especially γ- and δ-T3s, exhibited cytoprotective effects via activation of PI3K/Akt signaling pathway in a cellular PD model.
|
31619646 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results indicate that Res ameliorates 6-OHDA-induced apoptosis and motor dysfunction via activating the PI3K/Akt signaling pathway, delaying the progression of Parkinson's disease (PD) symptoms in this model.
|
31295526 |
2019 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vitexin protects dopaminergic neurons in MPTP-induced Parkinson's disease through PI3K/Akt signaling pathway.
|
29588573 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lentiviral Vector-Mediated SHC3 Silencing Exacerbates Oxidative Stress Injury in Nigral Dopamine Neurons by Regulating the PI3K-AKT-FoxO Signaling Pathway in Rats with Parkinson's Disease.
|
30184529 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson's Disease Dementia.
|
29515352 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inflammatory reactions and the PI3K/Akt pathway are strongly implicated in dopaminergic neuronal death in PD.
|
29435803 |
2018 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/AKT signaling mediated by G protein‑coupled receptors is involved in neurodegenerative Parkinson's disease (Review).
|
28000847 |
2017 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the data of the present study reported that anti‑inflammatory and neuroprotective effects can be obtained in BV2 microglial cells and in a mouse model of PD by successive activation of the SHH and PI3K/Akt signaling pathways.
|
28627590 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study firstly demonstrated that CXC195 protected against DA neurodegeneration in 6-OHDA-induced PD model by its anti-apoptotic properties and PI3K/Akt/GSK3β signaling pathway was involved in it.
|
28005221 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results showed that PF promoted dopamine neuron survival in vivo due to the MAO-B inhibition, and the PI3K/Akt signaling pathway may have mediated the protection of PF against MPTP, suggesting that PF treatment might represent a neuroprotective treatment for PD.
|
28093210 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Triggering of inflammasome by impaired autophagy in response to acute experimental Parkinson's disease: involvement of the PI3K/Akt/mTOR pathway.
|
28902711 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using the "weaver" mouse, a genetic model of PD, which exhibits progressive dopaminergic neurodegeneration in the Substantia Nigra (SN), we have shown that long-term administration (P1-P21) of BNN-20 almost fully protected the dopaminergic neurons and their terminals, via i) a strong anti-apoptotic effect, probably mediated through the Tropomyosin receptor kinase B (TrkB) neurotrophin receptor's PI3K-Akt-NF-κB signaling pathway, ii) by exerting an efficient antioxidant effect, iii) by inducing significant anti-inflammatory activity and iv) by restoring Brain-Derived Neurotrophic Factor (BDNF) levels.
|
28461162 |
2017 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The goal of the present study was to confirm VPA's dose-dependent neuroprotective propensities in the MPP<sup>+</sup> model of PD in primary dopamine (DA) neurons and to investigate the underlying molecular mechanisms using specific mitogen-activated protein kinases (MAPKs) and phosphatidylinositol 3-kinase- (PI3K-) Akt signaling inhibitors.
|
28421199 |
2017 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through PI3K/Akt and ERK signaling pathways.
|
28185818 |
2017 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of various signalling (Ras-MAPK, PI3K and AKT) pathways by augmented activity of neurotrophic factors (NTFs) could prevent or halt the progress of dopaminergic loss in Parkinson's disease (PD).
|
28181071 |
2017 |
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ovariectomized PD mice were treated with vehicle or icariin (3 days before MPTP injections) with or without the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or mitogen-activated protein kinase kinase (MEK) inhibitor PD98059.
|
28190476 |
2017 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that the anti-apoptotic PI3K/Akt pathway is over activated in PD, presumably as an effort to compensate for increased neuronal apoptosis and oxidative stress.
|
26806867 |
2016 |
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the basis of recent reports, we propose that impaired neurotrophin signaling (PI3k/Akt), low antioxidant levels, and generation of reactive oxygen species (ROS) conjointly participate in the progressive events responsible for the dopaminergic cell loss in Parkinson's disease (PD).
|
24528157 |
2014 |
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The estrogen receptor β-PI3K/Akt pathway mediates the cytoprotective effects of tocotrienol in a cellular Parkinson's disease model.
|
24768803 |
2014 |